CPAP or Zepbound? Patients, doctors debate sleep apnea treatment
Doctors favor treatment with continuous positive airway pressure, or CPAP, machines, researchers are slated to report this week at a meeting of the American Academy of Sleep Medicine. Adobe stock
June 9 (UPI) A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports.
Doctors favor treatment with continuous positive airway pressure, or CPAP, machines, researchers are slated to report this week at a meeting of the American Academy of Sleep Medicine. The machines keep airways open using mild air pressure provided through a mask patients wear while sleeping.
But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found.
"The results highlight a need for real-world comparative effectiveness data of CPAP versus tirzepatide, and a potential mismatch between patient and provider preferences when managing comorbid obesity and obstructive sleep apnea," lead researcher Ahmed Khalaf said in a news release.
He's a sleep technician in the pulmonary, critical care and sleep medicine division at University of California-San Diego.
Nearly 30 million adults in the United States have sleep apnea, a disease in which the upper airway collapses during sleep, causing people to wake repeatedly.
CPAP has been considered the gold standard for treating sleep apnea, but some patients find the machines too bulky and noisy.
About 50% of people prescribed CPAP either can't use it often enough to matter or find it too bothersome, according to Harvard Medical School. Common problems include mask discomfort, dry mouth, breathing that feels out of sync and noise from the machine.
Late last year, the U.S. Food and Drug Administration approved Zepbound as the first drug to treat people with obesity and sleep apnea.
At the time, the sleep medicine society hailed the approval as "a positive development for patients and clinicians, who now have another treatment option for this sleep disorder," according to a statement from the academy.
But Zepbound is only for people with obesity and sleep apnea, the society noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss, but might not cure the problem.
For the new study, researchers analyzed nationwide online survey data from 365 patients, and also spoke to 17 sleep medicine professionals at UCSD.
Doctors favored CPAP over Zepbound 53% to 26%, while patients favored Zepbound over CPAP 48% to 35%.
Both doctors and patients supported treatment that combined CPAP and Zepbound, but doctors were more enthusiastic about combination therapy, 88% versus 61%.
The patients' preferences are likely driven by their own experiences -- 78% said they were either current or former users of CPAP, results show.
By comparison, only 23% of patients said they'd ever used Zepbound or Ozempic (semaglutide), the other prominent GLP-1 drug.
Principal investigator Dr. Chris Schmickl, an assistant professor of medicine at University of California-San Diego, expressed surprise at the level of disagreement between patients and providers.
"Recognizing differing attitudes toward treatment is crucial for developing a realistic and achievable action plan," he said in a news release. "Additional research to understand the underlying reasons behind these preferences will offer valuable insights for providers to guide treatment decisions."
Researchers are scheduled to present these findings Wednesday at the society meeting in Seattle.
Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.
More information
Harvard Medical School has more on managing CPAP problems.
Copyright © 2025 HealthDay. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
Health care workers on alert for ICE raids in hospitals
President Trump's whittling away of protected places for immigrants has fueled fears among health care workers that Immigration and Customs Enforcement (ICE) agents will arrest patients in or around hospitals. In January, the Trump administration rescinded a Biden-era policy that protected certain areas like churches, schools and hospitals from immigration enforcement. And lawmakers in at least one state have introduced legislation aimed at making it easier for ICE to make arrests in hospitals. As the Department of Homeland Security (DHS) seeks to ramp up ICE raids at hotels, restaurants, farms and other sites, nurses worry their workplace could be next. 'We were all worried about what this meant,' Michael Kennedy, a nurse at a University of California, San Diego health facility located very near the U.S.-Mexico border, said of the policy changes under Trump. 'As we've seen these immigration raids ramp up, our first thought is about our patients and what that means for them.' ICE agents made a record number of migrant arrests in a single day this month and have appeared outside of courthouses in Seattle and stores in the New York City area. The agency's workplace raids in Los Angeles spurred days of protests, which in turn prompted a heavy-handed response from the Trump administration. Sandy Reding is a nurse at a hospital in Bakersfield, Calif., which serves communities of farm workers and employs a diverse staff. 'There is a lot of concern [about] ICE agents showing up with FBI or with the military, because we've seen a lot of reports on TV, and we have reports in our area where this is happening as well,' she said. Reding and her fellow nurses, she said, are also worried that the news of increased ICE raids will deter some patients from coming to the hospital to seek care. 'What we are going to see is a large burden on communities and hospitals if people delay care,' Reding said. 'And there are worse outcomes.' Nancy Hagan, an intensive care unit nurse at Maimonides Medical Center in New York City, said those concerns have come to fruition at her hospital. In May, she said, an immigrant New Yorker had appendicitis but waited too long to go to the emergency room. Their appendix burst, spreading infected tissue and bacteria to other organs, which ultimately killed them. 'Once patients hear that a hospital is no longer a safe place for them to go, they are afraid to come to the hospital,' she said. Hagan, a Haitian immigrant, added that she and her colleagues, who work at hospitals across the city, have noticed that emergency rooms appear to be emptier in recent months. Kennedy, the nurse in San Diego, said the Level 1 trauma center, which is typically packed, has been emptier than usual. He admitted the decline in patient visits could be seasonally related, but he said he believes that the possibility of ICE agents arresting immigrants is having a 'chilling effect.' 'I can't see how this doesn't affect our patients' willingness to seek care,' he said. 'I'm willing to bet that a lot of people are delaying care because they're afraid.' ICE did not get back to The Hill in response to questions on whether agents have arrested people in or around hospitals, or if there are plans to do so. DHS announced in January that it had rescinded former President Biden's guidelines on immigration enforcement at 'sensitive locations' that were first issued under former President Obama. 'The Trump Administration will not tie the hands of our brave law enforcement, and instead trusts them to use common sense,' a DHS spokesperson said at the time. The National Immigration Law Center said that while immigrants no longer have special protections at hospitals and other 'sensitive locations,' they still have basic rights. 'Instead, individuals will need to rely on basic constitutional protections in these spaces,' it said in a fact sheet. 'Specifically, the Fourth Amendment protects all individuals from unreasonable searches and seizures, and the Fifth Amendment ensures the right to remain silent when confronted by law enforcement.' The Emergency Medicine Residents' Association has distributed a flyer with step-by-step guidance for health care workers on dealing with ICE agents if they do enter hospitals. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
a day ago
- Yahoo
Judge blocks the Trump administration's National Science Foundation research funding cuts
BOSTON (AP) — A federal judge has blocked President Donald Trump 's administration from making drastic cuts to research funding provided by the National Science Foundation. U.S. District Judge Indira Talwani in Boston struck down on Friday a policy change that could have stripped universities of tens of millions of dollars in research funding. The universities argued the move threatened critical work in artificial intelligence, cybersecurity, semiconductors and other technology fields. Talwani said the change, announced by the NSF in May, was arbitrary and capricious and contrary to law. An email Saturday to the NSF was not immediately returned. At issue are 'indirect' costs, expenses such as building maintenance and computer systems that aren't linked directly to a specific project. Currently, the NSF determines each grant recipient's indirect costs individually and is supposed to cover actual expenses. The Trump administration has dismissed indirect expenses as 'overhead' and capped them for future awards by the NSF to universities at 15 % of the funding for direct research costs. The University of California, one of the plaintiffs, estimated the change would cost it just under $100 million a year. Judges have blocked similar caps that the Trump administration placed on grants by the Energy Department and the National Institutes of Health.
Bloomberg
a day ago
- Bloomberg
Chinese Biotech Showcases Challenger to Eli Lilly's Obesity Drug
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co. Hangzhou Sciwind Biosciences Co. said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at the highest dose. Although the trial did not compare ecnoglutide directly with existing medicines, the results were very similar to what Lilly's Zepbound showed in previous China studies, Sciwind Chief Executive Officer Hai Pan said in an interview.
